Subsidiary of Xizang Weixinkang Pharmaceutical (603676.SH) withdraws registration application for pediatric compound amino acid injection (20AA)

Xizang Weixinkang Pharmaceutical (603676.SH) announced that its wholly-owned subsidiary Inner Mongolia Baiyi Pharmaceutical Co., Ltd. (hereinafter referred to as "Baiyi Pharmaceutical") has received a "Notice of Termination of Drug Registration Application" issued by the National Medical Products Administration (hereinafter referred to as the "NMPA"), agreeing to withdraw the registration application for pediatric compound amino acid infusion (20AA). Pediatric compound amino acid infusion (20AA) is intended for intravenous enteral nutrition infusion for children and infants who are unable to take in nutrients orally or through the intestine, or have limited nutrient intake, as well as for newborns (including premature or low birth weight infants) requiring nutritional support. The withdrawal of the registration application for this drug will not have a significant impact on the company's current operations. Once the data information for this drug is improved, a new registration application will be submitted.